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Abstract
Septic encephalopathy is a devastating symptom of severe sepsis. Many studies have 
been performed to uncover the pathophysiological mechanisms of septic encephalopathy; 
however, novel technical approaches are still required to overcome this complex symptom. 
Because patients are suffering from severe cognitive impairment, coma, or delirium, 
which burden not only patients but also caregivers, overcoming septic encephalopathy is 
still a major social problem worldwide, especially in the intensive care. Septic encepha‐
lopathy seems to be caused by cytokine invasion and/or oxidative stress into the brain, 
and this pathological state leads to imbalance of neurotransmitters. In addition to this 
pathophysiology, septic encephalopathy causes complicated symptoms (e.g., ischemic 
stroke, edema, and aberrant sensory function). For these pathophysiological mecha‐
nisms, electrophysiology using animal models, positron emission tomography (PET), 
computed tomography, and magnetic resonance imaging for septic patients has provided 
important clues. However, the research for septic encephalopathy is currently confronted 
with the difficulty of complex symptoms. To overcome this situation, in this chapter, 
we introduce our novel methods for in vivo imaging of septic encephalopathy using 
near infrared (NIR) nanoparticles, quantum dots. In addition to our recent progress, we 
 propose a strategy for the future approach to in vivo imaging of septic encephalopathy.
Keywords: septic encephalopathy, molecular mechanism, in vivo imaging, quantum 
dots, disseminated intravascular coagulation
1. Introduction
Although the pathophysiological mechanism of septic encephalopathy (SE) still includes 
some mystery, recent progress of challenging research using animal models of sepsis has 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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gradually uncovered the molecular pathogenesis of SE. For instance, recent pathophysiologi‐
cal findings for SE include synaptic deficiency by interleukin‐1 beta [1] and acetylcholine [2] 
and brain ischemia or edema with disseminated intravascular coagulation (DIC) [3]. These 
phenomena are dynamically altered in a time‐dependent manner based on the content of 
 symptoms. Functional magnetic resonance imaging (fMRI) for patients of SE can describe 
the status of symptoms; however, it is difficult to track these time‐dependent changes in the 
septic brain because of the low time resolution of its measurement. To overcome this technical 
difficulty, we are working to develop noninvasive near infrared (NIR) imaging as a novel 
method to analyze the pathological state of SE.
In this chapter, we introduce current understanding of pathophysiology, the imaging 
technology, and the application of novel imaging technology to visualize the pathophysi‐
ological mechanism of SE. The contents are described as follows: (1) etiology of SE, (2) 
molecular mechanisms of pathogenesis, (3) NIR in vivo imaging, and (4) application to SE. 
In particular, we focus on DIC and our approach firstly demonstrates the novel application 
of NIR in vivo imaging to DIC. We expect that this review will be helpful to readers such 
as basic biomedical students, and scientists who are interested in the future preclinical and 
clinical application to SE.
2. Septic encephalopathy (SE)
Septic encephalopathy (SE) is a symptom with brain dysfunction caused by sepsis. Up to 70% 
of severe septic patients encountered developed SE [4]. Patients with SE are often  suffering 
from various neurological symptoms. Many research reports and reviews have discussed 
cognitive impairment [5, 6], delirium [7], coma [8–11], and recently seizure and aberrant sen‐
sory function [12–16]. In addition, complication symptoms such as ischemic stroke, edema, 
etc. occurred [17–19]. However, not all of pathophysiological mechanisms for SE have been 
clarified in Ref. [20], and a better understanding of SE is still an important social problem 
worldwide [21].
2.1. Etiology
The SE is often found in acute liver failure and cirrhosis patients and triggered by the various 
chemical mediators followed by systemic inflammatory response syndromes, whole‐body 
inflammation [22–24]. SE is different from the brain “encephalitis” which occurs due to patho‐
gens (e.g., bacteria, virus, etc.) direct invasion into the brain. Rather than the direct invasion, 
SE is caused indirectly by excessive inflammatory response (e.g., cytokine storm). Thus, SE 
is a symptom. Clinical studies for SE reported that patients with SE often suffered from 
hypotension [25], imbalance of amino acids in plasma [26], and neuronal injury with edema 
[27, 28]. Several lines of evidences suggest that a rodent model of SE showed aberrant behavior: 
altered sensory function [29, 30], increased anxiety [31, 32], and cognitive impairment [33]. 
These results are similar to the symptoms of brain dysfunction in SE patients [34]. Thus, 
neurological impairment leads to various symptoms in SE.
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3. Molecular mechanisms
3.1. Pathogenesis
To understand the molecular mechanisms, pathophysiological factors (e.g., imbalance of 
chemical substances, cellular environment, and molecules) are discussed. Overall pathogen‐
esis for SE is summarized in Figure 1. When SE is occurred, various chemical substances 
(e.g., neurotransmitter, modulator, etc.) were involved as reviewed elsewhere in Refs. [35, 36]. 
These chemical substances were mainly important for maintaining homeostasis in the normal 
condition. After the SE occurred, the imbalanced rate of substances (e.g., amino acids) [37–41] 
abrogated brain metabolic function (e.g., tryptophan metabolism) [42–44], microglial activa‐
tion in the brain followed by detachment of pericyte from microvascular basal lamina [45, 46].
Normally, the brain is protected with a barrier called blood brain barrier (BBB). The barrier 
consists of brain endothelial cells, and these cells are tightly attached with tight junction. The 
barrier is selectively permeable to transport of amino acid, gas, and lipid‐soluble chemicals 
which are important for neuronal function. Therefore, the inflammatory molecules cannot 
affect brain function in the normal condition because the brain is protected with blood brain 
barrier, and foreign substances are impeded by this barrier.
Figure 1. Overview of pathogenesis for septic encephalopathy (SE). Severe sepsis often results in septic encephalopathy, 
mainly followed by oxidative stress and cytokine storm. Accompanying BBB impairment and DIC, invaded 
inflammatory mediators cause aberrant neuronal function. PAMPs: pathogen‐associated molecular pattern; DAMPs: 
damage‐associated molecular patterns; BBB: blood brain barrier; IL: interleukin; TNF: tumor necrosis factor.
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In the septic condition, occurrence of systemic inflammatory response syndromes is followed 
by sepsis, the syndromes lead to destruction of this blood brain barrier [47, 48], and harmful 
chemical substances disrupt normal brain function. Then, the chemical substances cause 
the aberrant neuronal transmission and plasticity [1, 30]. The components of tight junctions 
are claudin, occludin, zona occludin, etc. [49]. This tight junction serves as if an adhesive 
of cells and underpins the blood brain barriers. Using a mouse model of sepsis, we clearly 
demonstrated that the occludin protein was destroyed 20 h after induction of sepsis and led 
to a permeabilization of cytokine [1, 30]. Other groups reported that tumor necrosis factor 
(TNF)‐alpha and calcium‐binding proteins were increased in the SE [50].
3.2. Blood brain barrier (BBB) impairment
Why was the tight junction disrupted? Overall mechanisms are still unclear, a hypothesis 
is, however, addressed. Neuroinflammation (e.g., microglia/macrophage activation, nitrogen 
oxide gas production) resulted in the mitochondria dysfunction with reactive oxygen syn‐
thesis (ROS) [51–55] and dysfunction of cerebrovascular endothelial cells [56]. The process is 
impeded by ROS inhibitors [57] or mitochondria‐targeted peptides [55].
Another hypothesis is as follows. Septic patients sometimes showed a rapid vasoconstriction 
of blood vessels, and this mechanical alteration may cause the damage to the microvascu‐
lature structure [58, 59]. Endothelin and its receptor which constrict blood vessels might be 
involved in that process [60, 61]. Phosphoinositide 3‐kinase cascade activated microglial cell 
and matrix metalloproteinase (i.e., marker of inflammation) and aggravated BBB impairment 
[62]. Consequently, the BBB disruption finally leads to the invasion of inflammatory mediators 
into the brain of SE [63].
3.3. Effect of cytokine storm on brain function
In any case, the dysfunction of blood brain barrier after sepsis increases the permeability of 
inflammatory molecules as described below and finally causes the brain malfunction.
For example, there are widely discussed cytokines such as interleukins (interleukin‐1, ‐6, ‐10) 
[37, 64], tumor necrosis factor (TNF)‐alpha [65, 66], complement C5a [67], and cascade [68]. 
Epigenetic modulation (e.g., histone acetylation) participates in the trigger of aberrant glu‐
tamate receptor subunits [29, 69] and causes memory deficit [70]. In addition, disseminated 
blood coagulation [71, 72] and oxidative stress [73–75] aggravated brain dysfunction of SE. 
MicroRNA (i.e., noncoding small RNA) involved in RNA silencing and posttranscriptional 
modification [76]. Besides nitric oxide (NO), lipid peroxidase, S100B protein [77], and the 
prion protein [78] may participate in SE.
3.4. Imbalance of synaptic transmissions on neurons
As a morphological study revealed that the neuronal spine was destabilized in a mouse model 
[79], neuronal environment may possibly be altered in SE. Actually, for other potent factors 
related to neurotransmission, norepinephrine [80], adrenergic system [81, 82], serotonergic 
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system [83], acetylcholine [84–86], gamma‐aminobutyric receptor A [87], N‐methyl‐D‐aspartate 
receptor 2B [29], and brain neurovascular dysfunction [88] were involved in the pathogenesis 
of SE. In summary, sepsis leads to the aberrant conditions in the neuronal and/or glial envi‐
ronments and may result in the devastating symptoms in the pathogenesis of SE.
4. Brain activity measurements: from electrophysiology to imaging
4.1. Electrophysiology
Neurophysiological studies have uncovered the neuronal dysfunction in SE. Neurophysiologists 
have developed various experimental techniques to study neuronal cell activity. Neuronal 
activities recordings can be classified as follows: (1) single neuronal activity and (2) multiple 
neuronal activity. To record the single neuronal activity, there are techniques such as patch 
clamp recording and intracellular recording.
On the other hand, to record multiple neuronal activity, there are several established 
 techniques. For example, there are field excitatory postsynaptic potentials (in vitro), local 
field potential (in vivo), and optical recording with voltage sensitive dye (in vitro and in 
vivo). For example, Kafa et al. reported reduced neuronal population activities in a rat 
model of SE [89], and Wang et al. also showed suppression of local field potentials dur‐
ing sensory stimulation in SE [30]. These findings are clearly similar to the clinical state of 
sensory dysfunction in septic patients [90]. It is useful to uncover the pathophysiological 
mechanism. These techniques are very powerful for studying the single neuron or sev‐
eral neurons in the local region of the brain. However, symptoms of SE are versatile with 
 complicated diseases (e.g., stroke, edema, myopathy, etc.) [35, 91, 92]. Integrative analysis 
with multiple viewpoints is still required [93].
4.2. Brain imaging
Noninvasive measurement was sought to determine the pathological state and followed by 
prognosis of SE [94]. Several research reports suggest that electroencephalogram (EEG) that 
placed to the surface of head was useful to study brain dysfunction by various encephalitis and 
encephalopathy [95, 96]. In SE, for example, the EEG recordings revealed decreased amplitudes 
of EEG signals [97]. Using a rat model, EEG signals were attenuated [83]. In addition, child 
patient with coma showed 6‐Hz burst firing pattern in SE [98]. Hence, EEG abnormality was 
found in the SE [99].
Why have these altered activity patterns due to brain dysfunction occurred? Functional 
 magnetic resonance imaging (fMRI) has been used to capture the pathological state of brain 
cortex in SE [100]. Clinically, patients of SE showed cerebral infarction with multiple ischemic 
stroke and white matter lesions [13, 101]. Additionally, cerebral edema was reported [102]. 
Recently, brain atrophy within the regions including amygdala, hippocampus, basal gan‐
glia, brainstem, thalamic, and cerebellar neurons was also shown in Ref. [103, 104]. Hence, 
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complicated symptoms, if they represent irreversible morphological alteration, have been 
found with fMRI. In addition to fMRI, positron emission tomography (PET) using 18  
F‐FDG was applied [105]; however, the application was limited. Conversely, reversible 
and time‐dependent altered symptoms (e.g., neuronal transmission) cannot be determined 
with fMRI imaging (and PET) [106]. Because fMRI takes 10–30 min or more to capture 
a brain image with the high spatial resolution, it only determines the stable state of the 
pathology for SE. To overcome this weak point, we are currently focused on the noninva‐
sive NIR imaging.
5. Near infrared (NIR) in vivo imaging
5.1. Probes
NIR imaging is a powerful tool for noninvasive in vivo imaging. Conventionally, visible light 
(400–700 nm) has been used for molecular fluorescent imaging in cellular dynamics [107, 108]. 
However, visible light is difficult to apply to deep‐tissue imaging because of the robust 
light absorption and scattering by intrinsic chromophores (hemoglobin, melanin, flavin, etc.) 
and organelles (mitochondria and cytoskeleton). Autofluorescence from tissues (heart, skin, and 
brain) which is excited by NIR light (700–1400 nm) is much lower than that by excited vis‐
ible light [109]. In addition, NIR light permeates tissues more than visible light (400–700 nm) 
(Figure 2). Therefore, the NIR light, especially 2nd optical window (1000–1400 nm), is currently 
expected to be applicable to noninvasive deep tissue imaging.
To label the target tissue, fluorescent probes are necessary. Compared to the visible light 
probes, NIR fluorescence probes are limited. For example, single‐walled carbon nanotubes 
(SWNTs), Ag
2
S quantum dots, PbS quantum dots, and rare‐earth‐doped nanocomposites are 
developed for 2nd optical windows for in vivo imaging (reviewed in Ref. [110]). We previously 
Figure 2. (a) Autofluorescence spectra of the dorsal side of a mouse body. The autofluorescence spectra were taken by 
excitation of 482, 670, and 785 nm. The dotted and solid arrows show the wavelength rage of 1st NIR optical window 
(I) and 2nd NIR optical window (II), respectively. (b) Absorption spectra of tissue slices of mouse skin, brain, and heart. 
Slice thickness of the skin, brain, and heart is 120, 100, and 200 μm, respectively. (Citation from Ref. [110]).
Sepsis136
compared these fluorescence probes in the same condition and found that PbS quantum dots 
were much brighter than other probes (Figure 3).
5.2. In vivo imaging
We applied PbS quantum dots (maximum fluorescence intensity: 1100 nm) from mouse tail 
vein and successfully recorded blood flow in the mouse head in a noninvasive manner [71] 
(Figure 4). The head of an anesthetized mouse was fixed on a stage of a microscope, and 
fluorescence was recorded through skin and skull (Figure 4a). The fluorescent intensity was 
recorded with InGaAs camera which is sensitive from 900–1600 nm. Soon after injection, brain 
blood vessels were visible on a mouse head (Figure 4b, right), and the picture was entirely 
similar to the image of blood vessels after scalp removal (Figure 4c, upper) and isolated brain 
(Figure 4c, lower). These findings suggest that the NIR in vivo imaging can visualize the brain 
blood flow non‐invasively. If we would like to apply this method to the pathophysiology of 
SE, what is the target?
Brain blood vessels are aggravated in SE. Previous reports addressed that, using an animal 
model, cerebral microcirculation was reported to be impaired [111]. Disseminated intravas‐
cular coagulation (DIC) is an important pathological state of sepsis and worsening of DIC 
increases multiple organ dysfunction. Anticoagulant therapy was performed, however, its 
effect was limited. Repetitive administration of anticoagulant drug increases the rate of 
side effects such as thrombocytopenia [112] and bleeding [113]. To find the pathological state 
of DIC, we examined whether NIR in vivo imaging detect DIC in the septic brain as described 
in the next section.
Figure 3. (a) Fluorescence spectra of nanomaterials that emit in the 2nd NIR window: SWNT, Ag
2
S QD, and PbS QD. 
(b) Bright field and fluorescence images (>1000 nm) of SWNT, Ag
2
S QD, and PbS QD. To compare the fluorescence 
brightness, absorbance at the excitation wavelength (720 nm) was adjusted to be the same value of 0.5 for SWNT, Ag
2
S 
QD, and PbS QD. (Citation from Ref. [110]).
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6. Application of NIR in vivo imaging to pathological analyses for septic 
encephalopathy
Next, we applied the NIR in vivo imaging to SE brain. To examine this, we studied whether 
DIC can be recorded with NIR imaging. Figure 5 demonstrated lipopolysaccharide (LPS)‐
induced DIC. Eighteen hours after LPS, clots (arrowheads) can be recorded noninvasively 
(Figure 5b, middle). In the isolated brain, the number of clots remarkably increased in the SE 
brain (Figure 6). Conversely, the increased clots were similar to the control level in the presence 
of heparin (i.e., inhibitor of clots formation), suggesting that the NIR imaging can record DIC 
in SE brain.
What is the importance of these findings? In blood vessels of the brain, tissue factor acti‐
vation including thrombin and fibrinogen which enhanced blood clot formation was 
occurred [114, 115], and this pathology finally led to multiple organ (e.g., lung, liver, 
 kidney, and brain, etc.) dysfunction [116]. However, it has been difficult to visualize the 
pathological state of DIC because of a lack of an effective biomarker [117]. Our present 
findings developed a novel approach to analyze the pathological state of brain blood 
 vessels in SE.
Figure 4. (a) Experimental setup for NIR fluorescence imaging of cerebral blood vessels. An anesthetized mouse was 
administered QD1100 in a caudal vein. An optical laser (785 nm wavelength) was used as an excitation light source, 
and NIR fluorescence was detected with an InGaAs camera; (b) imaging of a mouse head. Bright field image (left), 
NIR fluorescence image without QD administration (middle), and the NIR fluorescence image with QD administration 
(right). Scale bar: 1 mm; (c) NIR fluorescence images of cerebral blood vessels. Upper: fluorescence image after scalp 
removed, lower: fluorescence image after isolation. Scale bars: 1 mm. (Citation from Ref. [71]).
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Figure 5. (a) Time course of experimental procedure for lipopolysaccharide (LPS) and heparin administration; (b) 
NIR fluorescence images (>1000 nm) of cerebral blood vessels before and after administration of LPS (LPS (−) and LPS 
(+)), and the image following additional administration of heparin (LPS + heparin) with scalp removed. Lower panel 
shows the magnification of the images shown by red rectangles. Arrowheads show clots. Scale bars: 1 mm; (c) statistical 
analyses of the clots in the cerebral vessels. *: p < 0.05, number of mice: LPS (−): n = 5, LPS (+): n = 5, LPS + heparin: n = 3; 
(d) immunofluorescence staining of LPS‐treated cerebral blood vessels, where antifibrinogen antibody (Alexa Fluor 488) 
was used for staining of fibrinogen. Fibrinogen helps the formation of blood clots. Scale bar: 10 μm; (e) ELISA assays 
for thrombin–antithrombin complex (TAT) in blood plasma. *: p < 0.05, number of mice: LPS (−): n = 5, LPS (+): n = 5, 
LPS + heparin: n = 3. (Citation from Ref. [71]).
Figure 6. (a) Upper panel: NIR fluorescence images (>1000 nm) of cerebral blood vessels of isolated mouse brains. Left: 
LPS (−), Middle: LPS (+), Right: LPS + heparin. Red circles: clots. Blue squares: region of interests for the magnified 
views of lower panels. Scale bars: 1 mm. Lower panel: magnified NIR fluorescence image of cerebral blood vessels at the 
bregma. Red arrows: clots. Scale bars: 100 μm; (b) Number of clots for each mouse. *: p < 0.05, number of mice: LPS (−): 
n = 5, LPS (+): n = 5, LPS + heparin: n = 4. (Citation from Ref. [71]).
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7. Future prospect
In this chapter, we introduce the application of NIR in vivo imaging to SE. Currently, imaging 
technology is confronted with a turning point. Although there are several noninvasive  imaging 
technologies (PET, MRI, etc.), NIR noninvasive imaging can possibly record the faster time‐
dependent changes of pathological state in SE, though further developments of the imaging algo‐
rithm are required. In addition, the NIR imaging can label the distinct proteins by several specific 
antibodies and perform the multiple molecular in vivo imaging. Therefore, using the biomarker 
for SE, we may be able to visualize the novel pathophysiological mechanisms of SE.
Finally, in addition to our challenges, other candidate biomarkers which employ correlation 
to the pathological state of SE are recently addressed: S100β (i.e., astrocyte‐secreting protein) 
[77, 118–120], free radicals [121, 122], ascorbate [123–125], and various neuropeptides [126]. In 
addition, adult neurogenesis was induced in a rat model of SE and the neurogenesis marker 
(e.g., 5‐bromo‐2′‐deoxyuridine) might be useful [127]. In conclusion, these multidisciplinary 
approaches may overcome the pathophysiology and lead to innovative therapeutics for SE.
Acknowledgements
We thank Sumire Hino for secretary assistance, Dr. Jun Imamura for preparing Figure 1, 
Dr. Akitoshi Seiyama for critical reading of manuscript, and Kylius Wilkins for English 
 corrections. This work is supported by Grant‐in‐Aid for Scientific Research of YI (24592734).
Author details
Yukio Imamura1*, Yuki Murakami2, Naoya Matsumoto3, Hisatake Matsumoto3, Satoko Mitani4, 
Kentaro Shimizu3, Hiroshi Ogura3, Takeshi Shimazu3 and Takashi Jin1
*Address all correspondence to: yukio.imamura@riken.jp
1 Laboratory for Nano‐Bio Probes, Quantitative Biology Center, Riken, Japan
2 Laboratory of Developmental Neurobiology, Graduate School of Brain Science, Doshisha 
University, Japan
3 Department of Acute and Critical Care Center, Osaka University Hospital, Japan
4 Department of Nursing, School of Health Sciences, Gifu University of Medical Sciences, 
Gifu, Japan
References
[1] Imamura, Y., H. Wang, N. Matsumoto, T. Muroya, J. Shimazaki, H. Ogura, et al., 
Interleukin‐1beta causes long‐term potentiation deficiency in a mouse model of septic 
encephalopathy. Neuroscience. 2011; 187: 63‐69.
Sepsis140
[2] Rada, P., G.P. Mark, M.P. Vitek, R.M. Mangano, A.J. Blume, B. Beer, et al., Interleukin‐1 
beta decreases acetylcholine measured by microdialysis in the hippocampus of freely 
moving rats. Brain Res. 1991; 550(2): 287‐290.
[3] Polito, A., F. Eischwald, A.L. Maho, A. Polito, E. Azabou, D. Annane, et al., Pattern of 
brain injury in the acute setting of human septic shock. Crit Care. 2013; 17(5): R204, DOI: 
10.1186/cc12899.
[4] Gofton, T.E. and G.B. Young, Sepsis‐associated encephalopathy. Nat Rev Neurol. 2012; 
8(10): 557‐566.
[5] Streck, E.L., C.M. Comim, T. Barichello, and J. Quevedo, The septic brain. Neurochem 
Res. 2008; 33: 2171‐2177.
[6] Widmann, C.N. and M.T. Heneka, Long‐term cerebral consequences of sepsis. Lancet 
Neurol. 2014; 13(6): 630‐636, DOI: 10.1016/s1474‐4422(14)70017‐1.
[7] Tsuruta, R. and Y. Oda, A clinical perspective of sepsis‐associated delirium. J Intensive 
Care. 2016; 4: 18, DOI: 10.1186/s40560‐016‐0145‐4.
[8] Comim, C.M., L.C. Constantino, T. Barichello, E.L. Streck, J. Quevedo, and 
F. Dal‐Pizzol, Cognitive impairment in the septic brain. Curr Neurovasc Res. 2009; 
6: 194‐203.
[9] Luitse, M.J., C.J. van Asch, and C.J. Klijn, Deep coma and diffuse white matter abnor‐
malities caused by sepsis‐associated encephalopathy. Lancet. 2013; 381(9884): 2222, DOI: 
10.1016/s0140‐6736(13)60682‐0.
[10] Papadopoulos, M.C., D.C. Davies, R.F. Moss, D. Tighe, and E.D. Bennett, Pathophysiology 
of septic encephalopathy: a review. Crit Care Med. 2000; 28: 3019‐3024.
[11] Piva, S., V.A. McCreadie, and N. Latronico, Neuroinflammation in sepsis: sepsis 
 associated delirium. Cardiovasc Hematol Disord Drug Targets. 2015; 15(1): 10‐18.
[12] Berisavac, II, V.V. Padjen, M.D. Ercegovac, G. Beslac‐Bumbasirevic Lj, P. Stanarcevic, 
M.S. Stefanovic‐Budimkic, et al., Focal epileptic seizures, electroencephalography and 
outcome of sepsis associated encephalopathy‐A pilot study. Clin Neurol Neurosurg. 
2016; 148: 60‐66, DOI: 10.1016/j.clineuro.2016.06.013.
[13] Siami, S., D. Annane, and T. Sharshar, The encephalopathy in sepsis. Crit Care Clin. 
2008; 24(1): 67‐82, viii, DOI: 10.1016/j.ccc.2007.10.001.
[14] Yamaguchi, H., T. Tanaka, A. Maruyama, and H. Nagase, Septic encephalopathy 
 characterized by acute encephalopathy with biphasic seizures and late reduced  diffusion 
and early nonconvulsive status epilepticus. Case Rep Neurol Med. 2016; 2016: Article ID 
7528238, DOI: 10.1155/2016/7528238.
[15] Young, G.B., C.F. Bolton, T.W. Austin, Y.M. Archibald, J. Gonder, and G.A. Wells, The 
encephalopathy associated with septic illness. Clin Invest Med. 1990; 13: 297‐304.
[16] Ziaja, M., Septic encephalopathy. Curr Neurol Neurosci Rep. 2013; 13(10): 383, DOI: 
10.1007/s11910‐013‐0383‐y.
In Vivo Imaging of Septic Encephalopathy
http://dx.doi.org/10.5772/67983
141
[17] Kafa, I.M., I. Ari, and M.A. Kurt, The peri‐microvascular edema in hippocampal CA1 
area in a rat model of sepsis. Neuropathology. 2007; 27: 213‐220.
[18] Kondo, A., C. Sugiura, Y. Fujii, T. Inoue, Y. Maegaki, and K. Ohno, Fulminant sepsis‐
associated encephalopathy in two children: serial neuroimaging findings and clinical 
course. Neuropediatrics. 2009; 40(4): 157‐161, DOI: 10.1055/s‐0029‐1243626.
[19] Sari, A., S. Yamashita, S. Ohosita, H. Ogasahara, K. Yamada, A. Yonei, et al., Cerebro‐
vascular reactivity to CO
2
 in patients with hepatic or septic encephalopathy. Resuscitation. 
1990; 19(2): 125‐134.
[20] Sweis, R., J. Ortiz, and J. Biller, Neurology of Sepsis. Curr Neurol Neurosci Rep. 2016; 
16(3): 21, DOI: 10.1007/s11910‐016‐0623‐z.
[21] Lamar, C.D., R.A. Hurley, and K.H. Taber, Sepsis‐associated encephalopathy: review 
of the neuropsychiatric manifestations and cognitive outcome. J Neuropsychiatr 
Clin Neurosci. 2011; 23(3): 237‐241, DOI: 10.1176/appi.neuropsych.23.3.23710.1176/
jnp.23.3.jnp237.
[22] Gustot, T., F. Durand, D. Lebrec, J.L. Vincent, and R. Moreau, Severe sepsis in cirrhosis. 
Hepatology. 2009; 50: 2022‐2033.
[23] Rolando, N., J. Wade, M. Davalos, J. Wendon, J. Philpott‐Howard, and R. Williams, The 
systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000; 32(4 
Pt 1): 734‐739, DOI: 10.1053/jhep.2000.17687.
[24] Tsai, M.H., Y.S. Peng, Y.C. Chen, N.J. Liu, Y.P. Ho, J.T. Fang, et al., Adrenal insufficiency 
in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006; 43(4): 
673‐681, DOI: 10.1002/hep.21101.
[25] Wijdicks, E.F. and M. Stevens, The role of hypotension in septic encephalopathy 
 following surgical procedures. Arch Neurol. 1992; 49(6): 653‐656.
[26] Berg, R.M., S. Taudorf, D.M. Bailey, C. Lundby, F.S. Larsen, B.K. Pedersen, et al., Effects 
of lipopolysaccharide infusion on arterial levels and transcerebral exchange  kinetics 
of glutamate and glycine in healthy humans. Apmis. 2012; 120(9): 761‐766, DOI: 
10.1111/j.1600‐0463.2012.02904.x.
[27] Ari, I., I.M. Kafa, and M.A. Kurt, Perimicrovascular edema in the frontal cortex in a rat 
model of intraperitoneal sepsis. Exp Neurol. 2006; 198: 242‐249.
[28] Papadopoulos, M.C., F.J. Lamb, R.F. Moss, D.C. Davies, D. Tighe, and E.D. Bennett, 
Faecal peritonitis causes oedema and neuronal injury in pig cerebral cortex. Clin Sci. 
(Lond). 1999; 96: 461‐466.
[29] Imamura, Y., N. Yoshikawa, Y. Murkami, S. Mitani, N. Matsumoto, H. Matsumoto, et al., 
Effect of histone acetylation on N‐methyl‐D‐aspartate 2B receptor subunits and inter‐
leukin‐1 receptors in association with nociception‐related somatosensory  cortex dys‐
function in a mouse model of sepsis. Shock. 2016; 45(6): 660‐667, DOI: 10.1097/SHK. 
0000000000000547.
Sepsis142
[30] Wang, H., Y. Imamura, N. Matsumoto, N. Yoshikawa, J. Nakagawa, K. Yamakawa, et 
al., Matrix metalloproteinase‐9 triggers the gap junction impairment and somatosensory 
neuronal dysfunction in septic encephalopathy. Biochem Pharmacol: Open Access. 2013; 
02(01): 7, DOI: 10.4172/2167‐0501.1000108.
[31] Anderson, S.T., S. Commins, P.N. Moynagh, and A.N. Coogan, Lipopolysaccharide‐
induced sepsis induces long‐lasting affective changes in the mouse. Brain Behav Immun. 
2015; 43: 98‐109, DOI: 10.1016/j.bbi.2014.07.007.
[32] Calsavara, A.C., D.H. Rodrigues, A.S. Miranda, P.A. Costa, C.X. Lima, M.C. Vilela, 
et al., Late anxiety‐like behavior and neuroinflammation in mice subjected to  sublethal 
 polymicrobial sepsis. Neurotox Res. 2013; 24(2): 103‐108, DOI: 10.1007/s12640‐012‐ 
9364‐1.
[33] Michels, M., A.S. Vieira, F. Vuolo, H.G. Zapelini, B. Mendonca, F. Mina, et al., The 
role of microglia activation in the development of sepsis‐induced long‐term cognitive 
 impairment. Brain Behav Immun. 2015; 43: 54‐59, DOI: 10.1016/j.bbi.2014.07.002.
[34] Gupta, R., S. Saigal, R. Joshi, P. Tagore, N. Rai, and K. Prasad, Unrecognized catatonia as 
a cause for delayed weaning in Intensive Care Unit. Indian J Crit Care Med. 2015; 19(11): 
693‐694, DOI: 10.4103/0972‐5229.169360.
[35] Imamura, Y., S. Hori, N. Matsumoto, K. Yamakawa, J. Nakagawa, J. Shimazaki, et al., 
Septic encephalopathy. Encephalitis, Encephalomyelitis and Encephalopathies. Vol. 8. 
2013: Nova Science Publisher. 163‐176.
[36] Imamura, Y., H. Wang, N. Matsumoto, H. Ogura, T. Shimazu, T. Jin, et al., Neurochemistry 
in the pathophysiology of septic encephalopathy. Neuroscience‐Dealing with Frontiers 
ed. Neurochemistry, ed. M. Contreras. 2012, Croatias: In‐tech Open Access Publisher.
[37] Basler, T., A. Meier‐Hellmann, D. Bredle, and K. Reinhart, Amino acid imbalance early 
in septic encephalopathy. Intensive Care Med. 2002; 28: 293‐298.
[38] Berg, R.M., S. Taudorf, D.M. Bailey, C. Lundby, F.S. Larsen, B.K. Pedersen, et al., Cerebral 
net exchange of large neutral amino acids after lipopolysaccharide infusion in healthy 
humans. Crit Care. 2010; 14(1): R16, DOI: 10.1186/cc8873.
[39] Freund, H., S. Atamian, J. Holroyde, and J.E. Fischer, Plasma amino acids as predictors 
of the severity and outcome of sepsis. Ann Surg. 1979; 190: 571‐576.
[40] Nakamura, T., Y. Kawagoe, T. Matsuda, I. Ebihara, and H. Koide, Effects of polymyxin 
B‐immobilized fiber hemoperfusion on amino acid imbalance in septic encephalopathy. 
Blood Purif. 2003; 21: 282‐286.
[41] Takezawa, J., N. Taenaka, M.K. Nishijima, T. Hirata, T. Okada, Y. Shimada, et al., Amino 
acids and thiobarbituric acid reactive substances in cerebrospinal fluid and plasma of 
patients with septic encephalopathy. Crit Care Med. 1983; 11(11): 876‐879.
[42] Freund, H.R., M. Muggia‐Sullam, R. LaFrance, J. Holroyde, and J.E. Fischer, Regional 
brain amino acid and neurotransmitter derangements during abdominal sepsis and 
In Vivo Imaging of Septic Encephalopathy
http://dx.doi.org/10.5772/67983
143
 septic encephalopathy in the rat. The effect of amino acid infusions. Arch Surg. 1986; 
121: 209‐216.
[43] Gao, R., M.Q. Kan, S.G. Wang, R.H. Yang, and S.G. Zhang, Disrupted tryptophan 
 metabolism induced cognitive impairment in a mouse model of sepsis‐associated 
encephalopathy. Inflammation. 2016; 39(2): 550‐560, DOI: 10.1007/s10753‐015‐0279‐x.
[44] Sprung, C.L., F.B. Cerra, H.R. Freund, R.M. Schein, F.N. Konstantinides, E.H. Marcial, et 
al., Amino acid alterations and encephalopathy in the sepsis syndrome. Crit Care Med. 
1991; 19: 753‐757.
[45] Nishioku, T., S. Dohgu, F. Takata, T. Eto, N. Ishikawa, K.B. Kodama, et al., Detachment 
of brain pericytes from the basal lamina is involved in disruption of the blood‐brain bar‐
rier caused by lipopolysaccharide‐induced sepsis in mice. Cell Mol Neurobiol. 2009; 29: 
309‐316.
[46] Pytel, P. and J.J. Alexander, Pathogenesis of septic encephalopathy. Curr Opin Neurol. 
2009; 22: 283‐287.
[47] Ballabh, P., A. Braun, and M. Nedergaard, The blood‐brain barrier: an overview: struc‐
ture, regulation, and clinical implications. Neurobiol Dis. 2004; 16: 1‐13.
[48] Varatharaj, A. and I. Galea, The blood‐brain barrier in systemic inflammation. Brain 
Behav Immun. 2016; 60: 1‐12. DOI: 10.1016/j.bbi.2016.03.010.
[49] Nico, B. and D. Ribatti, Morphofunctional aspects of the blood‐brain barrier. Curr Drug 
Metab. 2012; 13: 50‐60.
[50] Zhang, L.N., X.H. Wang, L. Wu, L. Huang, C.G. Zhao, Q.Y. Peng, et al., Diagnostic and 
predictive levels of calcium‐binding protein A8 and tumor necrosis factor receptor‐asso‐
ciated factor 6 in sepsis‐associated encephalopathy: a prospective observational study. 
Chin Med J (Engl). 2016; 129(14): 1674‐1681, DOI: 10.4103/0366‐6999.185860.
[51] Berg, R.M., K. Moller, and D.M. Bailey, Neuro‐oxidative‐nitrosative stress in sepsis. J 
Cereb Blood Flow Metab. 2011; 31(7): 1532‐1544, DOI: 10.1038/jcbfm.2011.48.
[52] Bozza, F.A., J.C. D’Avila, C. Ritter, R. Sonneville, T. Sharshar, and F. Dal‐Pizzol, 
Bioenergetics, mitochondrial dysfunction, and oxidative stress in the pathophysiology of 
septic encephalopathy. Shock. 2013; 39(Suppl 1): 10‐16, DOI: 10.1097/SHK.0b013e31828 
fade1.
[53] Hara, N., M. Chijiiwa, M. Yara, Y. Ishida, Y. Ogiwara, M. Inazu, et al., Metabolomic 
 analyses of brain tissue in sepsis induced by cecal ligation reveal specific redox 
 alterations‐‐protective effects of the oxygen radical scavenger edaravone. Shock. 2015; 
44(6): 578‐584, DOI: 10.1097/shk.0000000000000465.
[54] Michels, M., L.G. Danielski, F. Dal‐Pizzol, and F. Petronilho, Neuroinflammation: 
microglial activation during sepsis. Curr Neurovasc Res. 2014; 11(3): 262‐270.
Sepsis144
[55] Wu, J., M. Zhang, S. Hao, M. Jia, M. Ji, L. Qiu, et al., Mitochondria‐targeted  peptide 
reverses mitochondrial dysfunction and cognitive deficits in sepsis‐associated 
 encephalopathy. Mol Neurobiol. 2015; 52(1): 783‐791, DOI: 10.1007/s12035‐014‐8918‐z.
[56] Handa, O., J. Stephen, and G. Cepinskas, Role of endothelial nitric oxide synthase‐
derived nitric oxide in activation and dysfunction of cerebrovascular endothelial cells 
during early onsets of sepsis. Am J Physiol Heart Circ Physiol. 2008; 295(4): H1712‐
H1719, DOI: 10.1152/ajpheart.00476.2008.
[57] Zhou, T., L. Zhao, R. Zhan, Q. He, Y. Tong, X. Tian, et al., Blood‐brain barrier dysfunction 
in mice induced by lipopolysaccharide is attenuated by dapsone. Biochem Biophys Res 
Commun. 2014; 453(3): 419‐424, DOI: 10.1016/j.bbrc.2014.09.093.
[58] Pierrakos, C., A. Antoine, D. Velissaris, I. Michaux, P. Bulpa, P. Evrard, et al., Transcranial 
doppler assessment of cerebral perfusion in critically ill septic patients: a pilot study. 
Ann Intensive Care. 2013; 3: 28, DOI: 10.1186/2110‐5820‐3‐28.
[59] Szatmari, S., T. Vegh, A. Csomos, J. Hallay, I. Takacs, C. Molnar, et al., Impaired cerebro‐
vascular reactivity in sepsis‐associated encephalopathy studied by acetazolamide test. 
Crit Care. 2010; 14: R50.
[60] Naito, Y., K. Yoshioka, K. Tanaka, K. Tatsumi, S. Kimura, and Y. Kasuya, Endothelin B 
receptor‐mediated encephalopathic events in mouse sepsis model. Life Sci. 2014; 118(2): 
340‐346, DOI: 10.1016/j.lfs.2014.03.012.
[61] Shimojo, N., S. Jesmin, S. Zaedi, S. Maeda, S. Gando, I. Yamaguchi, et al., Alterations of 
gene expressions of preproET‐1 and ET receptors in brains of endotoxemic Sprague‐
Dawley rats. Exp Biol Med. (Maywood). 2006; 231: 1058‐1063.
[62] Frister, A., C. Schmidt, N. Schneble, M. Brodhun, F.A. Gonnert, M. Bauer, et al., 
Phosphoinositide 3‐kinase gamma affects LPS‐induced disturbance of blood‐brain 
 barrier via lipid kinase‐independent control of cAMP in microglial cells. Neuromolecular 
Med. 2014; 16(4): 704‐713, DOI: 10.1007/s12017‐014‐8320‐z.
[63] Pierrakos, C., R. Attou, L. Decorte, A. Kolyviras, S. Malinverni, P. Gottignies, et al., 
Transcranial Doppler to assess sepsis‐associated encephalopathy in critically ill patients. 
BMC Anesthesiol. 2014; 14: 45, DOI: 10.1186/1471‐2253‐14‐45.
[64] Ji, M.H., L.L. Qiu, H. Tang, L.S. Ju, X.R. Sun, H. Zhang, et al., Sepsis‐induced selective 
parvalbumin interneuron phenotype loss and cognitive impairments may be mediated 
by NADPH oxidase 2 activation in mice. J Neuroinflammat. 2015; 12: 182, DOI: 10.1186/
s12974‐015‐0401‐x.
[65] Alexander, J.J., A. Jacob, P. Cunningham, L. Hensley, and R.J. Quigg, TNF is a key 
 mediator of septic encephalopathy acting through its receptor, TNF receptor‐1. 
Neurochem Int. 2008; 52: 447‐456.
[66] Erbas, O. and D. Taskiran, Sepsis‐induced changes in behavioral stereotypy in rats; 
involvement of tumor necrosis factor‐alpha, oxidative stress, and dopamine turnover. J 
Surg Res. 2014; 186(1): 262‐268, DOI: 10.1016/j.jss.2013.08.001.
In Vivo Imaging of Septic Encephalopathy
http://dx.doi.org/10.5772/67983
145
[67] Flierl, M.A., P.F. Stahel, D. Rittirsch, M. Huber‐Lang, A.D. Niederbichler, L.M. Hoesel, 
et al., Inhibition of complement C5a prevents breakdown of the blood‐brain barrier and 
pituitary dysfunction in experimental sepsis. Crit Care. 2009; 13: R12.
[68] Jacob, A., L.K. Hensley, B.D. Safratowich, R.J. Quigg, and J.J. Alexander, The role of the 
complement cascade in endotoxin‐induced septic encephalopathy. Lab Invest. 2007; 87: 
1186‐1194.
[69] Sui, D.M., Q. Xie, W.J. Yi, S. Gupta, X.Y. Yu, J.B. Li, et al., Resveratrol protects against 
sepsis‐associated encephalopathy and inhibits the NLRP3/IL‐1beta axis in microglia. 
Mediators Inflamm. 2016; 2016: 1045657 Article ID 1045657, DOI: 10.1155/2016/1045657.
[70] Fang, J., Y. Lian, K. Xie, S. Cai, and P. Wen, Epigenetic modulation of neuronal  apoptosis 
and cognitive functions in sepsis‐associated encephalopathy. Neurol Sci. 2014; 35(2): 
283‐288, DOI: 10.1007/s10072‐013‐1508‐4.
[71] Imamura, Y., S. Yamada, S. Tsuboi, Y. Nakane, Y. Tsukasaki, A. Komatsuzaki, et al., Near‐
infrared emitting PbS quantum dots for in vivo fluorescence imaging of the thrombotic 
state in septic mouse brain. Molecules. 2016; 21(8): 1080.
[72] Li, R., J. Tong, Y. Tan, S. Zhu, J. Yang, and M. Ji, Low molecular weight heparin prevents 
lipopolysaccharide induced‐hippocampus‐dependent cognitive impairments in mice. 
Int J Clin Exp Pathol. 2015; 8(8): 8881‐8891.
[73] Chen, Q., W. Yu, J. Shi, J. Shen, T. Gao, J. Zhang, et al., Insulin alleviates the inflammatory 
response and oxidative stress injury in cerebral tissues in septic rats. J Inflamm (Lond). 
2014; 11: 18, DOI: 10.1186/1476‐9255‐11‐18.
[74] Hernandes, M.S., J.C. D’Avila, S.C. Trevelin, P.A. Reis, E.R. Kinjo, L.R. Lopes, et al., The 
role of Nox2‐derived ROS in the development of cognitive impairment after sepsis. J 
Neuroinflammation. 2014; 11: 36, DOI: 10.1186/1742‐2094‐11‐36.
[75] Lin, H.C. and F.J. Wan, Hyperbaric oxygenation reduces overexpression of c‐Fos and 
oxidative stress in the brain stem of experimental endotoxemic rats. Intensive Care Med. 
2008; 34: 1122‐1132.
[76] Li, L., Q. Sun, Y. Li, Y. Yang, Y. Yang, T. Chang, et al., Overexpression of SIRT1 induced by 
resveratrol and inhibitor of miR‐204 suppresses activation and proliferation of microg‐
lia. J Mol Neurosci. 2015; 56(4): 858‐867. DOI: 10.1007/s12031‐015‐0526‐5.
[77] Hamed, S.A., E.A. Hamed, and M.M. Abdella, Septic encephalopathy: relationship to 
serum and cerebrospinal fluid levels of adhesion molecules, lipid peroxides and S‐100B 
protein. Neuropediatrics. 2009; 40: 66‐72.
[78] Liu, J., D. Zhao, C. Liu, T. Ding, L. Yang, X. Yin, et al., Prion protein participates in the 
protection of mice from lipopolysaccharide infection by regulating the inflammatory 
process. J Mol Neurosci. 2015; 55(1): 279‐287, DOI: 10.1007/s12031‐014‐0319‐2.
Sepsis146
[79] Kondo, S., S. Kohsaka, and S. Okabe, Long‐term changes of spine dynamics and microglia 
after transient peripheral immune response triggered by LPS in vivo. Mol Brain. 2011; 4: 27.
[80] Freund, H.R., M. Muggia‐Sullam, J. Peiser, and E. Melamed, Brain neurotransmitter  profile 
is deranged during sepsis and septic encephalopathy in the rat. J Surg Res. 1985; 38: 267‐271.
[81] Davies, D.C., Blood‐brain barrier breakdown in septic encephalopathy and brain 
tumours. J Anat. 2002; 200: 639‐646.
[82] Kadoi, Y., S. Saito, F. Kunimoto, T. Imai, and T. Fujita, Impairment of the brain beta‐
adrenergic system during experimental endotoxemia. J Surg Res. 1996; 61: 496‐502.
[83] Soejima, Y., Y. Fujii, T. Ishikawa, H. Takeshita, and T. Maekawa, Local cerebral glucose 
utilization in septic rats. Crit Care Med. 1990; 18: 423‐427.
[84] Dal‐Pizzol, F., C.D. Tomasi, and C. Ritter, Septic encephalopathy: does inflammation 
drive the brain crazy? Rev Bras Psiquiatr. 2014; 36(3): 251‐258.
[85] Zhang, Q.H., Z.Y. Sheng, and Y.M. Yao, Septic encephalopathy: when cytokines interact 
with acetylcholine in the brain. Mil Med Res. 2014; 12: 0, DOI: 10.1186/2054‐9369‐1‐20.
[86] Zhu, S.Z., W.P. Huang, L.Q. Huang, Y.L. Han, Q.P. Han, G.F. Zhu, et al., Huperzine 
A protects sepsis associated encephalopathy by promoting the deficient cholinergic 
 nervous function. Neurosci Lett. 2016; 631: 70‐78, DOI: 10.1016/j.neulet.2016.07.009.
[87] Serantes, R., F. Arnalich, M. Figueroa, M. Salinas, E. Andres‐Mateos, R. Codoceo, et al., 
Interleukin‐1beta enhances GABAA receptor cell‐surface expression by a phosphati‐
dylinositol 3‐kinase/Akt pathway: relevance to sepsis‐associated encephalopathy. J Biol 
Chem. 2006; 281: 14632‐14643.
[88] Taccone, F.S., S. Scolletta, F. Franchi, K. Donadello, and M. Oddo, Brain perfusion in 
sepsis. Curr Vasc Pharmacol. 2013; 11(2): 170‐186.
[89] Kafa, I.M., S. Bakirci, M. Uysal, and M.A. Kurt, Alterations in the brain electrical activity 
in a rat model of sepsis‐associated encephalopathy. Brain Res. 2010; 1354: 217‐226.
[90] Zauner, C., A. Gendo, L. Kramer, G.C. Funk, E. Bauer, P. Schenk, et al., Impaired 
 subcortical and cortical sensory evoked potential pathways in septic patients. Crit Care 
Med. 2002; 30: 1136‐1139.
[91] Bolton, C.F., Electrophysiologic studies of critically ill patients. Muscle Nerve. 1987; 
10(2): 129‐135, DOI: 10.1002/mus.880100205.
[92] Teener, J.W. and M.M. Rich, Dysregulation of sodium channel gating in critical illness 
myopathy. J Muscle Res Cell Motil. 2006; 27: 291‐296.
[93] Iacobone, E., J. Bailly‐Salin, A. Polito, D. Friedman, R.D. Stevens, and T. Sharshar, Sepsis‐
associated encephalopathy and its differential diagnosis. Crit Care Med. 2009; 37(10 
Suppl): S331‐S336, DOI: 10.1097/CCM.0b013e3181b6ed58.
In Vivo Imaging of Septic Encephalopathy
http://dx.doi.org/10.5772/67983
147
[94] Oddo, M. and F.S. Taccone, How to monitor the brain in septic patients? Minerva 
Anestesiol. 2015; 81(7): 776‐788.
[95] Kaplan, P.W. and A.O. Rossetti, EEG patterns and imaging correlations in encephalopa‐
thy: encephalopathy part II. J Clin Neurophysiol. 2011; 28(3): 233‐251, DOI: 10.1097/
WNP.0b013e31821c33a0.
[96] Young, G.B., C.F. Bolton, Y.M. Archibald, T.W. Austin, and G.A. Wells, The electro‐
encephalogram in sepsis‐associated encephalopathy. J Clin Neurophysiol. 1992; 9: 
145‐152.
[97] Lin, L.C., Y.Y. Chen, W.T. Lee, H.L. Chen, and R.C. Yang, Heat shock pretreatment 
 attenuates sepsis‐associated encephalopathy in LPS‐induced septic rats. Brain Dev. 
2010; 32: 371‐377.
[98] Bragatti, J.A., A.M. Mattos, H. Bastes, and R.S. Riesgo, Alpha coma pattern in a child. 
Clin EEG Neurosci. 2008; 39(4): 206‐209.
[99] Hosokawa, K., N. Gaspard, F. Su, M. Oddo, J.L. Vincent, and F.S. Taccone, Clinical 
 neurophysiological assessment of sepsis‐associated brain dysfunction: a systematic 
review. Crit Care. 2014; 18(6): 674, DOI: 10.1186/s13054‐014‐0674‐y.
[100] Stubbs, D.J., A.K. Yamamoto, and D.K. Menon, Imaging in sepsis‐associated 
encephalopathy[mdash]insights and opportunities. Nat Rev Neurol. 2013; 9(10): 551‐561, 
DOI: 10.1038/nrneurol.2013.177.
[101] Sharshar, T., R. Carlier, F. Bernard, C. Guidoux, J.‐P. Brouland, O. Nardi, et al., Brain 
lesions in septic shock: a magnetic resonance imaging study. Intensive Care Med. 2007; 
33(5): 798‐806, DOI: 10.1007/s00134‐007‐0598‐y.
[102] Bozza, F.A., P. Garteiser, M.F. Oliveira, S. Doblas, R. Cranford, D. Saunders, et al., 
Sepsis‐associated encephalopathy: a magnetic resonance imaging and spectroscopy 
study. J Cereb Blood Flow Metab. 2010; 30: 440‐448.
[103] Finelli, P.F. and D.F. Uphoff, Magnetic resonance imaging abnormalities with septic 
encephalopathy. J Neurol Neurosurg Psychiatry. 2004; 75: 1189‐1191.
[104] Gotz, T., A. Gunther, O.W. Witte, F.M. Brunkhorst, G. Seidel, and F. Hamzei, Long‐term 
sequelae of severe sepsis: cognitive impairment and structural brain alterations ‐ an 
MRI study (LossCog MRI). BMC Neurol. 2014; 14: 145, DOI: 10.1186/1471‐2377‐14‐145.
[105] Semmler, A., S. Hermann, F. Mormann, M. Weberpals, S.A. Paxian, T. Okulla, et al., 
Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J 
Neuroinflammation. 2008; 5: 38.
[106] Weberpals, M., M. Hermes, S. Hermann, M.P. Kummer, D. Terwel, A. Semmler, et 
al., NOS2 gene deficiency protects from sepsis‐induced long‐term cognitive deficits. J 
Neurosci. 2009; 29: 14177‐14184.
Sepsis148
[107] Joo, C., H. Balci, Y. Ishitsuka, C. Buranachai, and T. Ha, Advances in single‐molecule 
fluorescence methods for molecular biology. Annu Rev Biochem. 2008; 77: 51‐76, DOI: 
10.1146/annurev.biochem.77.070606.101543.
[108] Terai, T. and T. Nagano, Fluorescent probes for bioimaging applications. Curr Opin 
Chem Biol. 2008; 12(5): 515‐521, DOI: 10.1016/j.cbpa.2008.08.007.
[109] Weissleder, R., A clearer vision for in vivo imaging. Nat Biotechnol. 2001; 19(4): 316‐317, 
DOI: 10.1038/86684.
[110] Jin, T. and Y. Imamura, Applications of highly bright PbS quantum dots to non‐inva‐
sive near‐infrared fluorescence imaging in the second optical window. ECS J Solid 
State Sci Technol. 2016; 5(1): R3138‐R3145, DOI: 10.1149/2.0171601jss.
[111] Taccone, F.S., F. Su, C. Pierrakos, X. He, S. James, O. Dewitte, et al., Cerebral microcir‐
culation is impaired during sepsis: an experimental study. Crit Care. 2010; 14: R140.
[112] Blauhut, B., H. Kramar, H. Vinazzer, and H. Bergmann, Substitution of antithrombin 
III in shock and DIC: a randomized study. Thromb Res. 1985; 39(1): 81‐89.
[113] Iba, T., I. Nagaoka, and M. Boulat, The anticoagulant therapy for sepsis‐associated 
 disseminated intravascular coagulation. Thromb Res. 2013; 131(5): 383‐389, DOI: 
10.1016/j.thromres.2013.03.012.
[114] Semeraro, N., C.T. Ammollo, F. Semeraro, and M. Colucci, Sepsis‐associated dissemi‐
nated intravascular coagulation and thromboembolic disease. Mediterr J Hematol 
Infect Dis. 2010; 2(3): e2010024, DOI: 10.4084/MJHID.2010.024.
[115] ten Cate, H., S.H. Schoenmakers, R. Franco, J.J. Timmerman, A.P. Groot, C.A. Spek, et 
al., Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care 
Med. 2001; 29(7 Suppl): S95‐S97; discussion S97‐98.
[116] Ziaja, M., Sepsis and septic encephalopathy: characteristics and experimental models. 
Folia Neuropathol. 2012; 50(3): 231‐239.
[117] Zampieri, F.G., M. Park, F.S. Machado, and L.C. Azevedo, Sepsis‐associated encepha‐
lopathy: not just delirium. Clinics (Sao Paulo). 2011; 66(10): 1825‐1831.
[118] Panni, J.K. and M.K. Panni, Changes in S100B levels rather than absolute values may 
be a better marker of severity of septic encephalopathy. Br J Anaesth. 2008; 100(3): 419; 
author reply 419‐420, DOI: 10.1093/bja/aen009.
[119] Piazza, O., E. Russo, S. Cotena, G. Esposito, and R. Tufano, Elevated S100B levels do 
not correlate with the severity of encephalopathy during sepsis. Br J Anaesth. 2007; 
99(4): 518‐521, DOI: 10.1093/bja/aem201.
[120] Spapen, H., D.N. Nguyen, J. Troubleyn, L. Huyghens, and J. Schiettecatte, Drotrecogin 
alfa (activated) may attenuate severe sepsis‐associated encephalopathy in clinical sep‐
tic shock. Crit Care. 2010; 14: R54.
In Vivo Imaging of Septic Encephalopathy
http://dx.doi.org/10.5772/67983
149
[121] Towner, R.A., P. Garteiser, F. Bozza, N. Smith, D. Saunders, J.C. d’ Avila, et al., In 
vivo detection of free radicals in mouse septic encephalopathy using molecular MRI 
and immuno‐spin trapping. Free Radic Biol Med. 2013; 65: 828‐837, DOI: 10.1016/j.
freeradbiomed.2013.08.172.
[122] Yokoo, H., S. Chiba, K. Tomita, M. Takashina, H. Sagara, S. Yagisita, et al., Neuro‐
degenerative evidence in mice brains with cecal ligation and puncture‐induced sep‐
sis: preventive effect of the free radical scavenger edaravone. PLoS One. 2012; 7(12): 
e51539, DOI: 10.1371/journal.pone.0051539.
[123] Huang, Y.N., C.C. Lai, C.T. Chiu, J.J. Lin, and J.Y. Wang, L‐ascorbate attenuates the 
 endotoxin‐induced production of inflammatory mediators by inhibiting MAPK 
 activation and NF‐kappaB translocation in cortical neurons/glia Cocultures. PLoS One. 
2014; 9(7): e97276, DOI: 10.1371/journal.pone.0097276.
[124] Voigt, K., A. Kontush, H.J. Stuerenburg, D. Muench‐Harrach, H.C. Hansen, and K. 
Kunze, Decreased plasma and cerebrospinal fluid ascorbate levels in patients with sep‐
tic encephalopathy. Free Radic Res. 2002; 36: 735‐739.
[125] Wilson, J.X. and F. Wu, Vitamin C in sepsis. Subcell Biochem. 2012; 56: 67‐83, DOI: 
10.1007/978‐94‐007‐2199‐9_5.
[126] Pinheiro da Silva, F., M.C. Machado, and I.T. Velasco, Neuropeptides in sepsis: from 
brain pathology to systemic inflammation. Peptides. 2013; 44: 135‐138, DOI: 10.1016/j.
peptides.2013.03.029.
[127] Bakirci, S., I.M. Kafa, M. Uysal, and M. Ayberk Kurt, Increased adult neurogenesis in 
the subventricular zone in a rat model of sepsis. Neurosci Lett. 2011; 497(1): 27‐31, DOI: 
10.1016/j.neulet.2011.04.014.
Sepsis150
